BDTX Q2 2023 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

BDTXBlack Diamond Therapeutics, Inc.

$126M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$20M

Net Income

-$19M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$120M

Total Liabilities

$38M

Stockholders' Equity

$82M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$20M	-$23M	+13.6%
Net Income	-$19M	-$23M	+16.5%